

## ***SCANMED SUPPORTS EFFORTS TO DISCOVER FUTURE OF PRECISION CARE FOR PROSTATE CANCER***

The organizers of the [First Global Summit on Precision Diagnosis for Prostate Cancer](#) announced that Dr. Randy Jones, PhD., CEO at ScanMed, will participate as a featured speaker in the Session on Industrial Innovation at the September Summit. ScanMed is a bronze sponsor of the Summit.

The mission of this Summit—set for September 16-18 in Boston—is to educate key stakeholders about prostate diagnostics and their groundbreaking impact on precision care, including screening, early detection, and treatment.

For the first time, this Summit will bring together the key multi-disciplinary experts in the development, research and clinical implementation of biomarkers, imaging, genetics, genomics and other precision diagnostics, in order to review the state-of-the-art and emerging advances, to bridge the existing inter-disciplinary gaps, and to develop a consensus-based future vision for precision care and educational and scientific strategy for its realization.

“Academic and industrial collaborations have been critical for expediting development of precision diagnostics and their transfer from laboratories to patients,” said Dr. Faina Shtern, President & CEO of AdMeTech Foundation, and organizer of the Summit. “We are pleased that ScanMed is among our generous supporters and participants. Dr. Jones will review the critical steps in giving every man the best chance of precision, personalized prostate cancer care.”

The Summit is a key part of AdMeTech Foundation’s multi-faceted, statewide campaign, which has been creating a Massachusetts model of national and international leadership in prostate cancer research, education, and awareness.

For more information on the First Global Summit on Precision Diagnosis for Prostate Cancer, visit [www.admetech.org/summit](http://www.admetech.org/summit).

**About AdMeTech Foundation:** A 501(c)(3) nonprofit organization based in Boston, MA, AdMeTech Foundation established the Manogram® Project to create and expedite advancement of diagnostic tools for prostate cancer akin to life-saving mammograms. The Manogram® Project provides international leadership for groundbreaking programs in research, education, awareness and advocacy in order to advance early detection and treatment, which are critical for saving lives ([www.admetech.org](http://www.admetech.org)).

**About ScanMed:**

ScanMed was born of the need for superior quality products and service for the resonance imaging industry. When the quality and integrity of an image can have life-changing implications, the image truly becomes everything. With that in mind, ScanMed offers the world's first non-invasive, wearable, and highly accurate Prostate/Pelvic MRI Coil, making them an innovation leader in terms of offering viable diagnostic solutions to the masses. ScanMed's solution-based MRI coils are multi-functional and bring more coverage and wide-spread clinical application with a higher signal-to-noise ratio, solidifying the rank of frontrunner in the MRI coil industry.

**About FirstScan:**

FirstScan is the world's first low cost provider of MRI for Prostate Cancer screening. Utilizing ScanMed®'s patented flexible prostatic external antenna, this newly emerging technique can more accurately diagnose the probability of prostate cancer through digital imaging, with more accuracy (and fewer complications) than performing the currently standard medical practice of unguided TRUS biopsy alone. The exam is 100% non-invasive (no endorectal coils or contrast injections), and is performed in a state of the art, independent imaging facility located in Omaha, NE.

###